Other tumor type than adenocarcinoma 
Central nervous system (CNS) metastases or prior radiation for CNS metastases 
Gastric outlet obstruction or intestinal obstruction 
Evidence of gastrointestinal bleeding 
The patient has bony lesions as the sole evaluable disease. 
Past or concurrent history of neoplasm other than stomach cancer, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri 
Pregnant or lactating women, women of childbearing potential not employing adequate contraception 
Other serious illness or medical conditions 
Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry 
History of significant neurologic or psychiatric disorders including dementia or seizures 
Active uncontrolled infection 
Other serious underlying medical conditions which could impair the ability of the patient to participate in the study 
Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy 
concomitant drug medication; The following drugs cause drug interaction with S-1. 
i. Warfarin, phenprocoumon: increase bleeding tendency ii. Increase blood concentration of phenytoin iii. sorivudine: inhibit DPD -> increase toxicity according to fluoropyrimidine iv. allopurinol : decrease activity of S-1       
    

NCT00343668_exc_T1
Condition
adenocarcinoma
NCT00343668_exc_T2
Condition
tumor
NCT00343668_exc_T3
Condition
Central nervous system (CNS) metastases
NCT00343668_exc_T4
Procedure
radiation
NCT00343668_exc_T5
Condition
CNS metastases
NCT00343668_exc_T6
Condition
Gastric outlet obstruction
NCT00343668_exc_T7
Condition
intestinal obstruction
NCT00343668_exc_T8
Condition
gastrointestinal bleeding
NCT00343668_exc_T9
Observation
Evidence of
NCT00343668_exc_T10
Condition
bony lesions
NCT00343668_exc_T11
Value
the sole
NCT00343668_exc_T12
Qualifier
evaluable disease
NCT00343668_exc_T13
Observation
history of
NCT00343668_exc_T14
Condition
neoplasm
NCT00343668_exc_T15
Condition
stomach cancer
NCT00343668_exc_T16
Condition
non-melanoma skin cancer
NCT00343668_exc_T17
Condition
in situ carcinoma of the cervix uteri
NCT00343668_exc_T18
Procedure
treated
NCT00343668_exc_T19
Qualifier
curatively
NCT00343668_exc_T20
Scope
non-melanoma skin cancer or in situ carcinoma of the cervix uteri
NCT00343668_exc_T21
Condition
Pregnant
NCT00343668_exc_T22
Condition
lactating
NCT00343668_exc_T23
Person
women
NCT00343668_exc_T24
Condition
childbearing potential
NCT00343668_exc_T25
Person
women
NCT00343668_exc_T26
Procedure
contraception
NCT00343668_exc_T27
Negation
not employing
NCT00343668_exc_T28
Condition
serious illness
NCT00343668_exc_T29
Condition
medical conditions
NCT00343668_exc_T30
Condition
Unstable cardiac disease
NCT00343668_exc_T31
Procedure
treatment
NCT00343668_exc_T32
Condition
myocardial infarction
NCT00343668_exc_T33
Temporal
within 6 months prior to study entry
NCT00343668_exc_T34
Condition
neurologic disorders
NCT00343668_exc_T35
Condition
psychiatric disorders
NCT00343668_exc_T36
Condition
dementia
NCT00343668_exc_T37
Condition
seizures
NCT00343668_exc_T38
Scope
dementia or seizures
NCT00343668_exc_T39
Scope
neurologic or psychiatric disorders
NCT00343668_exc_T40
Observation
History
NCT00343668_exc_T41
Condition
infection
NCT00343668_exc_T42
Qualifier
uncontrolled
NCT00343668_exc_T43
Temporal
Active
NCT00343668_exc_T44
Condition
serious medical conditions
NCT00343668_exc_T45
Observation
ability of the patient to participate
NCT00343668_exc_T46
Drug
experimental drug
NCT00343668_exc_T47
Temporal
Concomitant
NCT00343668_exc_T48
Procedure
chemotherapy
NCT00343668_exc_T49
Procedure
hormonal therapy
NCT00343668_exc_T50
Procedure
immunotherapy
NCT00343668_exc_T51
Temporal
concomitant
NCT00343668_exc_T52
Scope
chemotherapy, hormonal therapy, or immunotherapy
NCT00343668_exc_T53
Drug
medication
NCT00343668_exc_T54
Drug
drug
NCT00343668_exc_T55
Temporal
concomitant
NCT00343668_exc_T56
Scope
drug medication
NCT00343668_exc_T57
Drug
Warfarin
NCT00343668_exc_T58
Drug
phenprocoumon
NCT00343668_exc_T59
Measurement
bleeding tendency
NCT00343668_exc_T60
Measurement
blood concentration of phenytoin
NCT00343668_exc_T61
Value
Increase
NCT00343668_exc_T62
Drug
sorivudine
NCT00343668_exc_T63
Drug
allopurinol
NCT00343668_exc_T64
Value
increase
NCT00343668_exc_T65
Drug
fluoropyrimidine
NCT00343668_exc_T66
Scope
childbearing potential not employing adequate contraception
NCT00343668_exc_T70
Negation
other than
NCT00343668_exc_T71
Negation
except for
NCT00343668_exc_T72
Negation
Other